Diabetes Mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group 1: In addition to anti diabetic drugs, a coded bottle containing type 1 diabetic capsules (each capsule containing dried aqueous extract of 100 mg of Thymus, 100 mg
Sponsors
Fasa University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Presence of diabetes (FBS>126 mg/dl) To have a FBS less than 270 and HgbA1c more than 5.6 Age between 30 to 65 Not to have any additional systemic diseases like; liver, renal, rheumatologic diseases or hypertension Not to consume any anti-diabetic or corticosteroid drugs 2 weeks before the study Not to drink alcohol or use opium To have a weight between 55-100 To have a BMI between 18 to 35
Exclusion criteria
Exclusion criteria: Not agree to participate in the study. To have a FBS more than 270 mg/dl Consuming corticosteroid drugs during the study Presence of any side effects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: At the beginning of intervention, after 4 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HgbA1C. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;??????? ???. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;BS2pp. Timepoint: At the beginning of intervention, after4 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;LDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning. Method of measurement: Venous blood sampling.;SGOT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;Alp. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;TG. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;SGPT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;PPAR?I gene expression. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;IGFBP-2 gene expression. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;IGFR gene expression. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of m | — |
Secondary
| Measure | Time frame |
|---|---|
| Satisfaction of patients. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Tolerance. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Temperament. Timepoint: At the beginning of the study. Method of measurement: Questionnaire.;Drug side effects. Timepoint: 3 months after recruitment. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNeda Jamshidi Gorki
Fasa University of Medical Sciences
Outcome results
None listed